epiglucan and Hyperinsulinism

epiglucan has been researched along with Hyperinsulinism* in 1 studies

Other Studies

1 other study(ies) available for epiglucan and Hyperinsulinism

Article	Year
An immunopotentiator of beta-1,6;1,3 D-glucan prevents diabetes and insulitis in BB rats. Diabetes research and clinical practice, 1992, Volume: 17, Issue:2 The preventive effect of an immunopotentiator, beta-1,6;1,3 D-glucan, on the development of diabetes and insulitis was studied in BB rats. The intravenous administration of 1 mg kg-1 week-1 of beta-1,6;1,3 D-glucan from the age of 4 weeks decreased the cumulative incidence of diabetes from 43.3% (13/30) to 6.7% (2/30) (P less than 0.005) and also the incidence of insulitis from 82.4% (14/17) to 26.3% (5/19) at the age of 20 weeks (P less than 0.002). Eight of nine rats were free from diabetes for 5 weeks after stopping beta-1,6;1,3 D-glucan at the age of 20 weeks. The total numbers of leukocytes in the peripheral blood and spleen of the rats were increased by beta-1,6;1,3 D-glucan treatment (P less than 0.05), whereas their T lymphocytes subsets were not changed. These data indicate that immunopotentiators could modulate the autoimmune mechanisms directed to pancreatic islets and inhibit the development of diabetes in BB rats. Topics: Adjuvants, Immunologic; Animals; Autoimmunity; Diabetes Mellitus, Type 1; Female; Glucans; Hyperinsulinism; Incidence; Injections, Intravenous; Leukocyte Count; Rats; Rats, Inbred BB; Rats, Wistar; T-Lymphocytes	1992

Article

Year

An immunopotentiator of beta-1,6;1,3 D-glucan prevents diabetes and insulitis in BB rats.

Diabetes research and clinical practice, 1992, Volume: 17, Issue:2

The preventive effect of an immunopotentiator, beta-1,6;1,3 D-glucan, on the development of diabetes and insulitis was studied in BB rats. The intravenous administration of 1 mg kg-1 week-1 of beta-1,6;1,3 D-glucan from the age of 4 weeks decreased the cumulative incidence of diabetes from 43.3% (13/30) to 6.7% (2/30) (P less than 0.005) and also the incidence of insulitis from 82.4% (14/17) to 26.3% (5/19) at the age of 20 weeks (P less than 0.002). Eight of nine rats were free from diabetes for 5 weeks after stopping beta-1,6;1,3 D-glucan at the age of 20 weeks. The total numbers of leukocytes in the peripheral blood and spleen of the rats were increased by beta-1,6;1,3 D-glucan treatment (P less than 0.05), whereas their T lymphocytes subsets were not changed. These data indicate that immunopotentiators could modulate the autoimmune mechanisms directed to pancreatic islets and inhibit the development of diabetes in BB rats.

Topics: Adjuvants, Immunologic; Animals; Autoimmunity; Diabetes Mellitus, Type 1; Female; Glucans; Hyperinsulinism; Incidence; Injections, Intravenous; Leukocyte Count; Rats; Rats, Inbred BB; Rats, Wistar; T-Lymphocytes

1992